PD22-05 tadalafil for male luts improves endothelial function
Abstract
RESULTS: There was no difference of IIEF-5, IPSS, Qmax, and PVR between two groups in V1.At V3, both groups had improvements of IPSS and group 2 had better improvements (-3.1Æ3.9 vs. -5.1Æ4.4 p<0.001).And Group 2 had larger improvements than Group 1 in Qmax significantly.No difference in PVR in both groups comparing V1 vs. V2 and V1 vs V3.Group 2 had better improved IIEF-5 than Group1 ( V1 vs. V3: 4.4 Æ 5.1vs.4.8 Æ 5.8; p ¼ 0.032).There was no drop out patients due to cardiovascular problems.CONCLUSIONS: Once daily mirodenafil 50mg was more ef?cacious in treating both ED and LUTS than on-demand dosing mirodenafil 100mg without any complication of cardiovascular problems.
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.